29th March 2022

Pharmanovia announces departure of Chief Corporate Development Officer Alastair Hay

LONDON – Alastair Hay is leaving his position as Chief Corporate Development Officer at the global pharmaceutical business, Pharmanovia, on March 31st, 2022.

Alastair was one of the founders of the business in 2014, joining as Chief Finance Officer when it was family-owned and had just four employees in a single office. In the last eight years, it has grown into a multi-national business, operating in more than 140 territories with more than 250 employees across 11 offices.

In 2021, Alastair took on the role of Chief Commercial Development Officer, responsible for growing the business through M&A and Product Development. He has worked on more than 17 established brand acquisitions during his time at the business, as well as two company acquisitions in the Nordics and Benelux. Pharmanovia now owns more than 20 iconic brands and has become a preferred partner for innovator pharma companies. 

Dr James Burt, Chief Executive, Pharmanovia, said:

“We are grateful to Alastair for the huge contribution he has made to the success of the business, helping it scale up into a fast-growth international pharmaceutical company. He has played a pivotal role in its growth, overseeing the acquisition of iconic medicines which we have revitalised for the benefit of patients around the world. We wish him the very best for the future.”

Alastair Hay said:

“It has been a great joy for me to play a part in the tremendous success of Pharmanovia. I would like to thank my colleagues, our shareholders and our innovator pharma partners for their huge support over the years. I would like to wish James and the new management team every success with their exciting plans for Pharmanovia.”


About Pharmanovia

Pharmanovia is a dynamic, fast-growing international pharmaceutical company with a portfolio of over 20 brands across more than 140 markets. Our mission is to improve patient health globally through the revitalisation of niche, tried-and-trusted medicines.

Since its inception in 2013, Pharmanovia has grown consistently year on year, focusing on delivering high-quality branded prescription medicines to patients, prescribers and healthcare providers across the world. Our growth has enabled the company to reinvest in its products, brands, people, and to give back to its communities. A people business with a strong, supportive culture that encourages innovation and entrepreneurial spirit, our team comprises over 250 employees and 29 nationalities, operating from offices in the UK, Denmark, Netherlands, Switzerland, U.A.E., India, Singapore, Italy and South Korea.

We are an agile and imaginative global specialty pharma business and aim to be a preferred partner for innovator pharma companies, instigating a paradigm shift in the life cycle management of iconic medicines.  We seek to extensively engage with clinical communities to communicate product improvements and prioritise environmental, social, and governance considerations across the business and workforce.

Pharmanovia’s therapeutic areas include Cardiovascular, Oncology, Endocrinology and Neurology.